INC Stock Overview
A dermatology and oncology therapeutics company, focuses on the dermatological formulation and delivery technologies for various indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Incanthera plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.14 |
| 52 Week High | UK£0 |
| 52 Week Low | UK£0 |
| Beta | 0.24 |
| 11 Month Change | -19.40% |
| 3 Month Change | -53.45% |
| 1 Year Change | 114.29% |
| 33 Year Change | 8.43% |
| 5 Year Change | n/a |
| Change since IPO | 28.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| INC | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -15.6% | 4.5% | 2.2% |
| 1Y | 114.3% | 0.7% | 8.0% |
Return vs Industry: INC exceeded the UK Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: INC exceeded the UK Market which returned 8% over the past year.
Price Volatility
| INC volatility | |
|---|---|
| INC Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: INC's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: INC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 7 | Simon Ward | www.incanthera.com |
Incanthera plc, a dermatology and oncology therapeutics company, focuses on the dermatological formulation and delivery technologies for various indications. It develops skincare products under the Skin + CELL brand name. The company was founded in 2010 and is headquartered in Manchester, the United Kingdom.
Incanthera plc Fundamentals Summary
| INC fundamental statistics | |
|---|---|
| Market cap | UK£15.78m |
| Earnings (TTM) | -UK£1.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.2x
P/E RatioIs INC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INC income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£1.55m |
| Earnings | -UK£1.55m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INC perform over the long term?
See historical performance and comparison